1.Munaya C. Bitter leaf-based extracts cures hepatitis co-inferation and others. The Guardian Newspaper, July, 25; 2013

2.Iroanya OO, Adebesin OA, Okpuzor J. Evaluation of the hepato and nephron-protective effect of a polyherbal mixture using Wistar albino rats. J Clin Diagn Res 2014;8:HC15-21.

3.Schiffers RR. African Indigenous Vegetables: An Overview of the Cultivated Species. Vol. 3. England: University Greenwich Press; 2000. p. 133-42

4.Ibrahim G, Abdurahman EM, Ibrahim H, Ibrahim NO. Comparative cytomorphological studies on the studies of V. amygdalina del. and V. kotschyama. Niger J Bot 2010;23:133-42.

5.Swee K, Wan Y, Ho B, Boo KH, Woon SL, Huyunh K, et al. An ethnoveterinary used green vegetables with multiple bioactivities. J Med Plant Res 2010;4:2787-812.

6.Abosi AO, Rasoreta BH. In-vivo anti-malarial activity of V. amygdalina Del. Br J Biomed Sci 2003;60:89-91

7.Marble A. Glibenclamide, a new sulphonylurea: Whither oral hypoglycaemic agents? Drugs 1971;1:109-15

8.Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care 1995;18:1113-23.

9.Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulindependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17

10.Akah P, Obioma N, Ada N, Dorathy A. Effects of aqueous leaf extract of Vernonia amygdalina on blood glucose and triglyceride levels of alloxan-induced diabetic rats (Rattus rattus). Anim Res Int 2004;1:90-4.

11.Akah PA, Okafor CL. Blood sugarlowering effects of Vernonia amygdalina del in an experimental rabbit model. Phytother Res 2006;6:171-3

12.Akah PA, Okafor CL. Blood sugarlowering effects of Vernonia amygdalina del in an experimental rabbit model. Phytother Res 2006;6:171-3

13.Katzung BG, Masters SB, Trevor AJ. Basic and Clinical Pharmacology. New York: McGraw-Hill Medical; 2009

14.Serrano-Martín X, Payares G, Mendoza-León A. Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis. Antimicrob Agents Chemother 2006;50:4214-6.

15.Rambiritch V, Naidoo P, Butkow N. Dose-response relationships of sulfonylureas: Will doubling the dose double the response? South Med J 2007;100:1132-6.

16.Jonsson A, Hallengren B, Rydberg T, Melander A. Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes. Diabetes Obes Metab 2001;3:403-409.